THE LONDON GAZETTE, 28TH NOVEMBER 1997

| Product Licence Number | Company Name | Product Name | Active Ingredients | Indications | Date of Authorisation |
|---------------------------|--|--|--|---|--------------------------|
| 00068/0178 | 3M Health Care Limited | EPAQ Inhaler | Salbutamol Sulphate 120-000 mcg | The management of bronchial asthma, for the relief of wheezing and shortness of breath used on as required basis. May be used as necessary to relieve attacks of acute dyspnoea and may be used prophylactically before exertion or to prevent exercise-induced asthma. May also be used in the treatment of reversible airways obstruction associated with chronic bronchitis and emphysema. Prescription Only Medicine | 11th August 1997 |
| 00101/0445 | Novartis Pharmaceuticals UK Limited | Rimactane Capsules 150 mg | Rifampicin EP 150-0 mg | A major drug in the management of tuberculosis (all forms) and certain opportunistic mycobacterial infections. It is effective in cases resistant to other anto-tuberculosis agents and shows no cross-resistance outside the Rifamycin group of drugs. In the treatment of tuberculosis Rimactane must always be combined with other antituberculosis agents. It is effective in combination with Isoniazid. Streptomycin, Pyrazinamide, Ethambutol and the majority of second line drugs. Is also indicated for the chemoprophylaxis of meningococcal meningitis. Prescription Only Medicine | lst August 1997 |
| 00101/0446 | Novartis Pharmaceuticals UK Limited | Rimactane Capsules 300 mg | Rifampicin EP 300-0 mg | (See PL/0101/0445) Prescription Only Medicine | 1st August 1997 |
| 00101/0447 | Novartis Pharmaceuticals UK Limited | Rimactane Infusion 300 mg | Rifampicin Sodium Salt 308-2 mg (Equivalent to Rifampicin (Rimactane) BP 300-0 mg) | As for PL/00101/0445 and Rimactane infusion is indicated in patients with all forms of tuberculosis who are unable to tolerate oral therapy. e.g. postoperative or comatose patients or patients in whom gastro-intestinal absorption is impaired. | lst August 1997 |
| 00101/0448 | Limited | Rimactane Syrup 100 mg/5 ml | | Prescription Only Medicine The management of tuberculosis (all forms) and certain opportunistic mycobacterial infections. It is effective in cases resistant to other anti-tuberculosis agents and shows no cross- resistance outside the rifampycin group of drugs. In the treatment of tuberculosis it must always be combined with other anti- tuberculosis agents. It is effective in combination with isoniazid, streptomycin, pyrazinamide, ethambutol and the majority of second line drugs. Also indicated for the chemoprophylaxis of meningococcal meningitis. Prescription Only Medicine | Ist August 1997 |
| 00101/0449 | Novartis Pharmaceuticals UK Limited | | Rifampicin EP 165-0 mg Isoniazid EP 100-0 mg | Rimactane and isoniazid are both major drugs in the management of tuberculosis and in certain opportunist mycobacterial infections. Rifampicin is effective in cases resistant to other antituberculous agents and shows no cross-resistance outside the rifamycin group of drugs. Rimactazid must always be used in combination with other antituberculous agents, e.g. streptomycin, pyrazinamide, ethambutol and the majority of second-line drugs. | lst August 1997 |
| 00101/0450 | Novartis Pharmaceuticals UK Limited | | Rifampicin EP 330-00 mg Isoniazid EP 150-00 mg | (See PL/00101/0449) Prescription Only Medicine | 1st August 1997 |
| 00101/0529 | Novartis Pharmaceuticals UK Limited | Sodium Chloride 0-9% w/v Sterile Aqueous Suspension Medium | None | Not applicable (to be used as a suspension medium for a prescription only medicine). Prescription Only Medicine | 17th November 1997 |
| 00142/0436 | A H Cox & Company Limited | Indomethacin Modified Release Capsules Pardelprin MR Capsules 75 mg | Indomethacin 75-000 mg | Non-steroidal analgesic and anti- inflammatory agent indicated in active rheumatoid arthritis. osteoarthritis, ankylosing spondylitis, degenerative joint disease of the hip, acute musculoskeletal disorders and low back pain. Also indicated in periarticular disorders such as bursitis, tendinitis, synovitis, tenosynovitis and capsulitis. Also indicated in inflammation, pain and oedema following orthopaedic procedures and the treatment of pain and associated symptons of primary dysmenorrhoca. | 12th August 1997 |
| 00223/0045 | Seton Healthcare Group plc | Ibuprofen Tublets 400 mg | Ibuprofen 400-000 mg | For its anti-inflammatory and analgesic effect in the treatment of Rheumatoid Arthritis (including | 31st October 1997 |